I’ve spent 25 years in venture capital. Here’s how it quietly shut ordinary Americans out of the AI wealth boom—and what could fix it

The article argues that the biggest growth companies are increasingly staying private longer, with capital concentrating in names like OpenAI, Anthropic, SpaceX and Anduril instead of reaching public markets. It cites regulatory burden, litigation risk and accredited-investor restrictions as key reasons, while proposing shareholder tort reform and a U.S. sovereign wealth fund as structural fixes. The piece is a policy-oriented commentary rather than a company-specific update, so immediate market impact is limited.

Analysis

The investable implication is not simply “more private capital,” but a persistent rerating of the entire late-stage venture stack. As elite companies defer IPOs, price discovery migrates from public comps to private secondaries and crossover rounds, which should keep the valuation premium concentrated in a narrow set of platform winners while starving the mid-tier of liquidity and attention. That tends to favor firms with direct access to growth-round allocation and hurt public-market “future IPO” baskets that rely on a steady supply of listings.

Second-order, the biggest public-market losers are not the obvious names but the enablers: exchange operators, small-cap brokers, and litigation-sensitive software/hardware names that once depended on the IPO funnel for customer growth and M&A optionality. If the public window stays structurally shut for 12-24 months, expect a continued shrinking of the small-cap ecosystem, lower retail participation, and weaker demand for sell-side research, all of which reinforce the cycle. The article’s policy fix is directionally bullish for broad participation, but the path dependency is high; legislative reform is a multi-year process, while the private-market disintermediation is happening now.

The contrarian view is that the “public market is being hollowed out” narrative may be overstated near term because higher rates and volatile equity markets still make private capital look attractive on a risk-adjusted basis even without regulation. In other words, the current equilibrium may persist because it is economically rational, not merely because it is politically entrenched. The real catalyst that could reverse this is a sustained bull market in small-cap equities or a regulatory shock that cuts litigation risk and compliance drag enough to reopen the IPO funnel.

Key Decisions for Investors

• Underweight IPO-exposed small-cap financial intermediaries and exchanges over the next 6-12 months; the slower listing pipeline reduces transaction volumes and research monetization. Favor larger diversified platforms with recurring fee streams over capital-markets-dependent brokers.
• Long quality private-market access via public proxies: add exposure to firms monetizing crossover/private secondary demand, while avoiding baskets that need broad IPO issuance to work. Risk/reward is favorable over 12-24 months as the private premium persists.
• Pair trade: long mega-cap AI beneficiaries with strong balance sheets and private-market optionality, short small-cap growth indices. The spread should widen if late-stage capital remains concentrated and public-market breadth keeps deteriorating.
• Buy downside protection on small-cap growth / IPO indices for 6-9 months via puts or put spreads. The thesis breaks only if issuance accelerates materially or a policy surprise lowers the cost of being public.
• Watch for a policy catalyst in 2026 election season; if litigation reform or expanded retail access to private vehicles gains traction, rotate from defensives into broad-market beneficiaries of a reopened IPO cycle.